Magnitude and Determinants of Placebo Response in Acute Migraine Trials

BACKGROUND AND OBJECTIVES: Migraine is a highly prevalent and disabling neurologic disorder. Beyond drug-specific mechanisms, the role of contextual, individual-related, and disease-related factors remains poorly characterized. We quantified placebo response in randomized controlled trials (RCTs) of acute migraine treatments and identified patient-level, drug-level, and study-level determinants. METHODS: This meta-analytic review searched PubMed, Embase, Cochrane Central, ClinicalTrials.gov, and the European and Japanese Trial Registers from inception to November 2025 for published/unpublished, double-blind, parallel-group, phase 2 or 3 RCTs evaluating acute pharmacologic migraine treatments. Placebo rates with 95% CIs and prediction intervals (PIs) were pooled using random-effects models. Subgroup analyses and meta-regressions explored potential drivers. The primary outcome was 2-hour pain freedom after placebo administration. Secondary outcomes included 2-hour pain relief, sustained pain freedom, rescue medication use, global impression of improvement, and most bothersome symptom (MBS) freedom. RESULTS: < 0.001), even after multivariable adjustment. Placebo rates were 34% for 2-hour pain relief, 9% for sustained pain freedom, 52% for rescue medication use, 24% for positive global impression, and 34% for MBS freedom. Exploratory analyses of pain relief showed high placebo responses among non-Caucasian individuals, in Asian countries, and in gepant RCTs. DISCUSSION: Placebo response represents a substantial and increasing component of outcomes in acute migraine RCTs. Improved trial design, standardized communication, and transparent reporting may enhance effect-size interpretation and preserve assay sensitivity in future trials.